期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55
卷 55, 期 -, 页码 613-631出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-010814-124852
关键词
blood-brain barrier; biologics; receptor-mediated transport; antibody; transferrin receptor; insulin receptor; low density lipoprotein receptor
资金
- NHGRI NIH HHS [T32 HG002760] Funding Source: Medline
- NIGMS NIH HHS [T32 GM008349] Funding Source: Medline
- NINDS NIH HHS [R01 NS071513] Funding Source: Medline
Biologics are an emerging class of medicines with substantial promise to treat neurological disorders such as Alzheimer's disease, stroke, and multiple sclerosis. However, the blood-brain barrier (BBB) presents a formidable obstacle that appreciably limits brain uptake and hence the therapeutic potential of biologics following intravenous administration. One promising strategy for overcoming the BBB to deliver biologics is the targeting of endogenous receptor-mediated transport (RMT) systems that employ vesicular trafficking to transport ligands across the BBB endothelium. If a biologic is modified with an appropriate targeting ligand, it can gain improved access to the brain via RMT. Various RMT-targeting strategies have been developed over the past 20 years, and this review explores exciting recent advances, emphasizing studies that show brain targeting in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据